Treatment of Macular Edema after Pars Plana Vitrectomy for Idiopathic Epiretinal Membrane Using Intravitreal Dexamethasone Implant: Long-Term Outcomes

Autor:	Eleni Dimitriou, Panagiotis Theodossiadis, Dimitrios Kazantzis, George Theodossiadis, Irini Chatziralli, Alexandros Chatzirallis
Rok vydání:	2019
Předmět:	Male Pars plana medicine.medical_specialty Visual acuity genetic structures medicine.medical_treatment Visual Acuity Vitrectomy 01 natural sciences Dexamethasone Macular Edema 03 medical and health sciences 0302 clinical medicine Ophthalmology medicine Humans Prospective Studies 0101 mathematics Prospective cohort study Glucocorticoids Macular edema Aged Drug Implants business.industry 010102 general mathematics Epiretinal Membrane General Medicine Middle Aged medicine.disease eye diseases Sensory Systems Treatment Outcome medicine.anatomical_structure Intravitreal Injections 030221 ophthalmology & optometry Female sense organs Implant Epiretinal membrane medicine.symptom business Tomography Optical Coherence medicine.drug
Zdroj:	Ophthalmologica. 242:16-21
ISSN:	1423-0267 0030-3755
DOI:	10.1159/000496705
Popis:	Purpose: The aim of this study was to investigate the efficacy and safety of intravitreal dexamethasone implant for the treatment of macular edema after pars plana vitrectomy (PPV) for epiretinal membrane (ERM) removal. Methods: This prospective study included 27 patients who were diagnosed with macular edema after PPV for ERM removal and who were treated with either intravitreal dexamethasone implant (n = 15) or were observed without intervention (n = 12). Changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were assessed 1, 6, and 12 months ­after treatment. Results: Patients treated with intravitreal dexamethasone implant showed significant improvement in BCVA and reduction in CRT at months 1, 6, and 12 after treatment, while patients in the control group showed improvement that did not reach statistical significance. The two groups differed significantly in terms of BCVA and CRT at all time points of the follow-up period, in favor of the dexamethasone implant group. Eighty percent of the patients treated with intravitreal dexamethasone needed only one implant until month 12, while no serious adverse events were noticed in any group. Conclusions: Intravitreal dexamethasone implant was found to be effective and safe for the treatment of macular edema after PPV for ERM removal.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc83e32f70d2dcddb2add1d87180cd0 https://doi.org/10.1159/000496705 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.